Alkermes vs Nasus Pharma
Alkermes reported revenue of $1.5 billion in fiscal 2025, 1.2 times Nasus Pharma's $1.2 billion in fiscal 2025. Alkermes had an operating margin of 17.2%, against -0.4% at Nasus Pharma. Free cash flow was $480 million at Alkermes and −$5 million at Nasus Pharma.
Side by side
| Alkermes | Nasus Pharma | |
|---|---|---|
| Latest fiscal year | FY2025, Dec 31, 2025 | FY2025, Dec 31, 2025 |
| Revenue | $1.5B | $1.2B |
| Revenue growth | −5.2% | — |
| Revenue growth a year, last 5 years | 7.3% | — |
| Gross margin | 86.7% | — |
| Operating margin | 17.2% | −0.4% |
| Net margin | 16.4% | −0.5% |
| Free cash flow | $480M | −$5M |
| Free cash flow margin | 32.5% | −0.4% |
| Return on capital | — | — |
| Net debt to EBITDA | — | — |
| Dividends and buybacks | $0M | $0M |
| Change in diluted share count | −0.3% | 14.0% |
| Last close | $46.18 | $2.55 |
| P/E at the last close | — | — |
| Insider trades, last 12 months | sold $10.0 million | bought $61,809, sold $0 |
| Piotroski F-score | — | — |
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.
Ten years
Revenue
US$ billions, fiscal years
AlkermesNasus Pharma
Operating margin
Percent of revenue
AlkermesNasus Pharma
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
AlkermesNasus Pharma
Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Alkermes and Nasus Pharma pages.